1: Schildberg FA, Klein SR, Freeman GJ, Sharpe AH. Coinhibitory Pathways in the
B7-CD28 Ligand-Receptor Family. Immunity. 2016 May 17;44(5):955-72. doi:
10.1016/j.immuni.2016.05.002. Review. PubMed PMID: 27192563; PubMed Central
PMCID: PMC4905708.


2: Sakai S, Kauffman KD, Sallin MA, Sharpe AH, Young HA, Ganusov VV, Barber DL.
CD4 T Cell-Derived IFN-γ Plays a Minimal Role in Control of Pulmonary
Mycobacterium tuberculosis Infection and Must Be Actively Repressed by PD-1 to
Prevent Lethal Disease. PLoS Pathog. 2016 May 31;12(5):e1005667. doi:
10.1371/journal.ppat.1005667. eCollection 2016 May. PubMed PMID: 27244558; PubMed
Central PMCID: PMC4887085.


3: Saha A, O'Connor RS, Thangavelu G, Lovitch SB, Dandamudi DB, Wilson CB,
Vincent BG, Tkachev V, Pawlicki JM, Furlan SN, Kean LS, Aoyama K, Taylor PA,
Panoskaltsis-Mortari A, Foncea R, Ranganathan P, Devine SM, Burrill JS, Guo L,
Sacristan C, Snyder NW, Blair IA, Milone MC, Dustin ML, Riley JL, Bernlohr DA,
Murphy WJ, Fife BT, Munn DH, Miller JS, Serody JS, Freeman GJ, Sharpe AH, Turka
LA, Blazar BR. Programmed death ligand-1 expression on donor T cells drives
graft-versus-host disease lethality. J Clin Invest. 2016 Jul 1;126(7):2642-60.
doi: 10.1172/JCI85796. Epub 2016 Jun 13. PubMed PMID: 27294527; PubMed Central
PMCID: PMC4922691.


4: Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett
RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q,
Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, 
Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM,
Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe
AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Analysis 
of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers
of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer
Discov. 2016 Aug;6(8):827-37. doi: 10.1158/2159-8290.CD-15-1545. Epub 2016 Jun
14. PubMed PMID: 27301722; PubMed Central PMCID: PMC5082984.


5: Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D,
Kwiatkowski D, O'Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo
AB, Bellmunt J, Callahan M, Cha EK, Drake C, Jarow J, Kamat A, Kim W, Knowles M, 
Mann B, Marchionni L, McConkey D, McShane L, Ramirez N, Sharabi A, Sharpe AH,
Solit D, Tangen CM, Amiri AT, Van Allen E, West PJ, Witjes JA, Quale DZ. Summary 
and Recommendations from the National Cancer Institute's Clinical Trials Planning
Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder
Cancer. 2016 Apr 27;2(2):165-202. PubMed PMID: 27376138; PubMed Central PMCID:
PMC4927845.


6: Ron-Harel N, Santos D, Ghergurovich JM, Sage PT, Reddy A, Lovitch SB, Dephoure
N, Satterstrom FK, Sheffer M, Spinelli JB, Gygi S, Rabinowitz JD, Sharpe AH,
Haigis MC. Mitochondrial Biogenesis and Proteome Remodeling Promote One-Carbon
Metabolism for T Cell Activation. Cell Metab. 2016 Jul 12;24(1):104-17. doi:
10.1016/j.cmet.2016.06.007. PubMed PMID: 27411012; PubMed Central PMCID:
PMC5330619.


7: Dobbins J, Gagnon E, Godec J, Pyrdol J, Vignali DA, Sharpe AH, Wucherpfennig
KW. Binding of the cytoplasmic domain of CD28 to the plasma membrane inhibits Lck
recruitment and signaling. Sci Signal. 2016 Jul 26;9(438):ra75. doi:
10.1126/scisignal.aaf0626. PubMed PMID: 27460989.


8: Rigas D, Lewis G, Aron JL, Wang B, Banie H, Sankaranarayanan I, Galle-Treger
L, Maazi H, Lo R, Freeman GJ, Sharpe AH, Soroosh P, Akbari O. Type 2 innate
lymphoid cell suppression by regulatory T cells attenuates airway hyperreactivity
and requires inducible T-cell costimulator-inducible T-cell costimulator ligand
interaction. J Allergy Clin Immunol. 2016 Oct 4. pii: S0091-6749(16)31087-9. doi:
10.1016/j.jaci.2016.08.034. [Epub ahead of print] PubMed PMID: 27717665; PubMed
Central PMCID: PMC5378695.


9: McArdel SL, Brown DR, Sobel RA, Sharpe AH. Anti-CD48 Monoclonal Antibody
Attenuates Experimental Autoimmune Encephalomyelitis by Limiting the Number of
Pathogenic CD4+ T Cells. J Immunol. 2016 Oct 15;197(8):3038-3048. Epub 2016 Aug
31. PubMed PMID: 27581174; PubMed Central PMCID: PMC5356934.


10: Karunarathne DS, Horne-Debets JM, Huang JX, Faleiro R, Leow CY, Amante F,
Watkins TS, Miles JJ, Dwyer PJ, Stacey KJ, Yarski M, Poh CM, Lee JS, Cooper MA,
Rénia L, Richard D, McCarthy JS, Sharpe AH, Wykes MN. Programmed Death-1 Ligand
2-Mediated Regulation of the PD-L1 to PD-1 Axis Is Essential for Establishing
CD4(+) T Cell Immunity. Immunity. 2016 Aug 16;45(2):333-45. doi:
10.1016/j.immuni.2016.07.017. PubMed PMID: 27533014.


11: Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC, Shan Q, Hale JS,
Lee J, Nasti TH, Sharpe AH, Freeman GJ, Germain RN, Nakaya HI, Xue HH, Ahmed R.
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy.
Nature. 2016 Sep 15;537(7620):417-421. doi: 10.1038/nature19330. Epub 2016 Aug 2.
PubMed PMID: 27501248; PubMed Central PMCID: PMC5297183.


12: Sage PT, Ron-Harel N, Juneja VR, Sen DR, Maleri S, Sungnak W, Kuchroo VK,
Haining WN, Chevrier N, Haigis M, Sharpe AH. Suppression by T(FR) cells leads to 
durable and selective inhibition of B cell effector function. Nat Immunol. 2016
Dec;17(12):1436-1446. doi: 10.1038/ni.3578. Epub 2016 Oct 3. PubMed PMID:
27695002.


13: Sharpe AH. Introduction to checkpoint inhibitors and cancer immunotherapy.
Immunol Rev. 2017 Mar;276(1):5-8. doi: 10.1111/imr.12531. PubMed PMID: 28258698; 
PubMed Central PMCID: PMC5362112.


14: Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, Konieczny BT,
Daugherty CZ, Koenig L, Yu K, Sica GL, Sharpe AH, Freeman GJ, Blazar BR, Turka
LA, Owonikoko TK, Pillai RN, Ramalingam SS, Araki K, Ahmed R. Rescue of exhausted
CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science. 2017 Mar
31;355(6332):1423-1427. doi: 10.1126/science.aaf0683. Epub 2017 Mar 9. PubMed
PMID: 28280249.


15: Juneja VR, McGuire KA, Manguso RT, LaFleur MW, Collins N, Haining WN, Freeman
GJ, Sharpe AH. PD-L1 on tumor cells is sufficient for immune evasion in
immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017 Apr
3;214(4):895-904. doi: 10.1084/jem.20160801. Epub 2017 Mar 16. PubMed PMID:
28302645.